CD274 and diffuse large B-cell lymphoma: Over the last ten years, immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have demonstrated significant efficacy in treating various solid tumors and hematologic malignancies, like Hodgkin lymphoma, and there was considerable optimism that similar results will be obtained in DLBCL.